Many patients with thalidomide embryopathy (TE) are now approaching middle age, and are anxious about issues such as their health and that of their family members, growing nursing care needs, and financial problems associated with retirement (Yoshizawa, Kimura, & Moriyoshi, 2012). Kruse et al. (2012) described how reduced physical function and pain experienced by TE Patients threatens their daily lives, explaining that the secondary sequelae (e.g., numbness and paralysis) and pain that develop with age, as well as associated difficulties with moving the body and physical fatigue,